{"id":1067885,"date":"2021-01-09T07:58:46","date_gmt":"2021-01-09T12:58:46","guid":{"rendered":"https:\/\/www.immortalitymedicine.tv\/leading-biosciences-announces-positive-topline-data-from-open-label-gastrointestinal-surgery-study\/"},"modified":"2024-08-18T11:40:31","modified_gmt":"2024-08-18T15:40:31","slug":"leading-biosciences-announces-positive-topline-data-from-open-label-gastrointestinal-surgery-study","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/leading-biosciences-announces-positive-topline-data-from-open-label-gastrointestinal-surgery-study.php","title":{"rendered":"Leading BioSciences Announces Positive Topline Data from Open-Label Gastrointestinal Surgery Study"},"content":{"rendered":"<p><![CDATA[CARLSBAD, Calif., Jan.  08, 2021  (GLOBE NEWSWIRE) -- Leading BioSciences, Inc. (\u201cLBS\u201d), a privately held company that recently entered into a definitive agreement for a reverse merger with Seneca Biopharma, Inc. (Nasdaq:SNCA) to form Palisade Bio, Inc. announced today that data from an open-label study demonstrated that patients treated with LB1148 had a statistically significant shorter length of stay in the hospital than the expected length of stay based on their billing code at admission.]]><\/p>\n<p>Read the original here:<br \/>\n<a target=\"_blank\" rel=\"nofollow noopener noreferrer\" href=\"http:\/\/www.globenewswire.com\/news-release\/2021\/01\/08\/2155561\/0\/en\/Leading-BioSciences-Announces-Positive-Topline-Data-from-Open-Label-Gastrointestinal-Surgery-Study.html?f=22&amp;fvtc=5&amp;fvtv=46634288\" title=\"Leading BioSciences Announces Positive Topline Data from Open-Label Gastrointestinal Surgery Study\">Leading BioSciences Announces Positive Topline Data from Open-Label Gastrointestinal Surgery Study<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Read the original here: Leading BioSciences Announces Positive Topline Data from Open-Label Gastrointestinal Surgery Study <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/leading-biosciences-announces-positive-topline-data-from-open-label-gastrointestinal-surgery-study.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":64,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246886],"tags":[],"class_list":["post-1067885","post","type-post","status-publish","format-standard","hentry","category-global-news-feed"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1067885"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/64"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=1067885"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1067885\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=1067885"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=1067885"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=1067885"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}